Cellect Biotechnology Ltd. was founded in 2011 by Kasbian Nuriel Chirich, Dr. Shai Yarkoni with a vision of enabling regenerative medicine to become reality. Realizing that stem cells are one of the pillars of the 21st century medicine, first development was around enabling the mass enrichment of stem cells as a raw material for any and all regenerative treatments. Without such technologies, stem cells based treatments will remain within the confines of laboratories and clinical trials. For regenerative medicine to become publicly available for all people, quality stem cells need to become a commodity, easily available in mass for all medicinal purposes. Cellect was driven by its wish to become the main provider of technologies for pharma companies and medical centers that will make the production of stem cells based products a trivial, safe and inexpensive process. Source
No articles found.
Intellia Therapeutics is a leading genome editing company focused on developing cu...
Intellia Therapeutics is a leading genome editi...
VBI Vaccines Inc. (Nasdaq: VBIV) is a commercial-stage biopharmaceutical company d...
VBI Vaccines Inc. (Nasdaq: VBIV) is a commercia...
Assembly Biosciences is advancing a new class of oral therapeutics for the treatme...
Assembly Biosciences is advancing a new class o...
Siemens Healthineers AG is the holding company of the Siemens Healthineers group. ...
Siemens Healthineers AG is the holding company ...
Halozyme is a clinical-stage biotechnology company focused on developing and comme...
Halozyme is a clinical-stage biotechnology comp...
Applied Science Products operates Advanced Plasma Products, Inc., a science and en...
Applied Science Products operates Advanced Plas...
PolarityTE is a commercial-stage biotechnology and regenerative biomaterials compa...
PolarityTE is a commercial-stage biotechnology ...
BioCardia, Inc., headquartered in San Carlos, California, is developing regenerati...
BioCardia, Inc., headquartered in San Carlos, C...
Join the National Investor Network and get the latest information with your interests in mind.